Intuitive Surgical, Inc. $ISRG Shares Sold by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.4% in the first quarter, Holdings Channel.com reports. The fund owned 5,812 shares of the medical equipment provider’s stock after selling 1,490 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Intuitive Surgical were worth $2,679,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Intuitive Surgical by 1.0% in the 4th quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after purchasing an additional 162,264 shares in the last quarter. Capital World Investors raised its holdings in Intuitive Surgical by 1.7% in the fourth quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock valued at $4,449,491,000 after buying an additional 127,526 shares during the period. Norges Bank purchased a new position in Intuitive Surgical in the fourth quarter valued at approximately $2,856,987,000. Invesco Ltd. lifted its position in Intuitive Surgical by 17.4% during the fourth quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after buying an additional 611,268 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Intuitive Surgical by 9.4% during the fourth quarter. Wellington Management Group LLP now owns 3,445,880 shares of the medical equipment provider’s stock valued at $1,951,609,000 after buying an additional 294,651 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the sale, the executive vice president directly owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the completion of the transaction, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. This trade represents a 46.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 7,169 shares of company stock valued at $3,059,135. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Trading Up 2.5%

ISRG opened at $388.97 on Thursday. Intuitive Surgical, Inc. has a twelve month low of $378.50 and a twelve month high of $603.88. The firm has a market cap of $137.76 billion, a price-to-earnings ratio of 47.15, a PEG ratio of 3.09 and a beta of 1.46. The company has a fifty day simple moving average of $418.39 and a 200 day simple moving average of $469.98.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 EPS. On average, analysts forecast that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. TD Cowen dropped their price objective on shares of Intuitive Surgical from $585.00 to $520.00 and set a “buy” rating for the company in a research report on Monday. Robert W. Baird lifted their target price on shares of Intuitive Surgical from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. JPMorgan Chase & Co. decreased their price target on shares of Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Jefferies Financial Group lowered their price target on Intuitive Surgical from $560.00 to $515.00 and set a “hold” rating for the company in a report on Wednesday, April 22nd. Finally, Truist Financial cut their price objective on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $565.31.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating, adding to the case that Intuitive Surgical can continue to defend its leadership in robotic surgery. BMO Capital Starts Intuitive Surgical (ISRG) at Outperform
• Positive Sentiment: Several articles note that ISRG heads into earnings with strong procedure momentum, da Vinci 5 adoption, and a history of beating estimates, which supports hopes for another solid quarter. Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
• Positive Sentiment: Intuitive Surgical’s Ion lung biopsy study is approaching a data readout, highlighting a potential new growth avenue beyond core robotic surgery. Intuitive Surgical’s Ion Lung Biopsy Study Nears Data Readout, Eyeing New Growth in Diagnostics
• Neutral Sentiment: Commentary around Intuitive Surgical’s leadership versus rising global competition is mixed: the company is using AI features and a broad ecosystem to defend share, but competition remains a watch item. Can ISRG Defend Its Leadership as Global Competition Intensifies?
• Neutral Sentiment: Some coverage frames the move as a pre-earnings repositioning event, with investors weighing recent analyst target cuts, margin pressure from tariffs, and broader medical-device weakness more than any new company-specific setback. Intuitive Surgical Falls as Target Cut and Pre-Earnings Jitters Weigh on Shares

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.